Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients

BACKGROUND: Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β(2)-agonist approved for chronic obstructive pulmonary disease. In the development of a once daily, inhaled fixed dose combination (FDC) of indacaterol, glycopyrronium bromide (a long-acting muscarinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, David, Vaidya, Soniya, Jauernig, Juergen, Ethell, Brian, Wagner, Kristina, Radhakrishnan, Rajkumar, Tillmann, Hanns-Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513528/
https://www.ncbi.nlm.nih.gov/pubmed/32967685
http://dx.doi.org/10.1186/s12931-020-01501-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513528/
https://www.ncbi.nlm.nih.gov/pubmed/32967685
http://dx.doi.org/10.1186/s12931-020-01501-1

Ejemplares similares